Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492399 | 0.88 | PGD (0.36) | PGDPDE4APGK1PGK2 | |
| SCHEMBL3492395 | 0.86 | PGD (0.37) | PGDPGK1PGK2TSHRMPI | |
| SCHEMBL7715581 | 0.77 | MPI (0.33) | MPI | |
| SCHEMBL1976284 | 0.77 | MPI (0.33) | MPI | |
| SCHEMBL7715583 | 0.77 | MPI (0.33) | MPI | |
| SCHEMBL23925241 | 0.75 | PDE4A (0.39) | PDE4ATSHRCYP2C9 | |
| SCHEMBL373264 | 0.75 | PDE4A (0.39) | PDE4ATSHRCYP2C9 | |
| SCHEMBL6258700 | 0.75 | PDE4A (0.39) | PDE4ATSHRCYP2C9 | |
| SCHEMBL645759 | 0.75 | PDE4A (0.39) | PGDPDE4ATSHRCYP2C9 | |
| SCHEMBL1143744 | 0.75 | PDE4A (0.39) | PGDPDE4ATSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799803-B2 | Hydroxamic acid compounds and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2010-09-21 | — | — | US | disclosed |
| EP-1613592-A4 | HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF | SLOAN KETTERING INST CANCER (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-07-05 | — | — | US | disclosed |
| US-7199134-B2 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1613592-A2 | HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040266818-A1 | Hydroxamic acid compounds and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-12-30 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004089293-A2 | HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
| EP-0275139-B1 | ASSAY METHOD USING PARTICLES WITH ASSOCIATED FLUORESCER | SYNTEX (U.S.A.) INC. (US) | 1992-04-15 | — | — | EP | disclosed |
| US-4891324-A | FLUORIMETRY | SYNTEX (U.S.A.) INC. (US) | 1990-01-02 | — | — | US | disclosed |
| EP-0275139-A2 | Assay method using particles with associated fluorescer | SYNTEX (U.S.A.) INC. (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155785-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | PGD 2711/4885PDE4A 3621/4885PGK1 2253/4885 |
| US-20040266818-A1 | Hydroxamic acid compounds and methods of use thereof | HDAC5, BRDT, HDAC1 | PGD 2711/4885PDE4A 3621/4885PGK1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.